CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed
Drug / intervention
fos-amprenavir calcium, ritonavir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00335270
NCT00335270Phase 4Completed
CompareCT.gov

A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination

Duke University·interventional·Posted Jun 9, 2006·Updated May 14, 2013

In Brief

A Phase 4 clinical trial evaluating fos-amprenavir calcium, ritonavir and abacavir/lamivudine as Epzicom for HIV. Completed, across 1 site.

Detailed Summary

The purpose of this study is to evaluate the antiretroviral efficacy, safety, and tolerability of fos-amprenavir boosted with either of two doses of ritonavir (RTV) when administered in combination with ABC/3TC (abacavir/lamivudine, Epzicom®) FDC (fixed dose combination) in a once-daily regimen over 96 weeks in ART-naïve, HIV-infected adults

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 9, 2006
Enrollment StartMar 1, 2006
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.1 years ago

Interventions

fos-amprenavir calcium, ritonavirdrug

abacavir/lamivudine as Epzicomdrug